Silva Arslanian1, Laure El Ghormli2, Fida Bacha3, Sonia Caprio4, Robin Goland5, Morey W Haymond3, Lynne Levitsky6, Kristen J Nadeau7, Neil H White8, Steven M Willi9. 1. Children's Hospital of Pittsburgh, Pittsburgh, PA. 2. Biostatistics Center, George Washington University, Rockville, MD elghorml@bsc.gwu.edu. 3. Texas Children's Hospital, Baylor College of Medicine, Houston, TX. 4. Yale University School of Medicine, New Haven, CT. 5. Columbia University, New York, NY. 6. Massachusetts General Hospital for Children, Boston, MA. 7. University of Colorado Anschutz Medical Campus, Aurora, CO. 8. Washington University in St. Louis, St. Louis, MO. 9. Children's Hospital of Philadelphia, Philadelphia, PA.
Abstract
OBJECTIVE: The Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) study demonstrated that glycemic failure rates in the three treatments combined-metformin plus rosiglitazone, metformin alone, and metformin plus lifestyle-were higher in non-Hispanic blacks (NHB; 52.8%) versus non-Hispanic whites (NHW; 36.6%) and Hispanics (H; 45.0%). Moreover, metformin alone was less effective in NHB versus NHW versus H youth. This study describes treatment-associated changes in adiponectin, insulin sensitivity, and β-cell function over time among the three racial/ethnic groups to understand potential mechanism(s) responsible for this racial/ethnic disparity. RESEARCH DESIGN AND METHODS: TODAY participants underwent periodic oral glucose tolerance tests to determine insulin sensitivity, C-peptide index, and oral disposition index (oDI), with measurements of total and high-molecular-weight adiponectin (HMWA). RESULTS: At baseline NHB had significantly lower HMWA than NHW and H and exhibited a significantly smaller increase (17.3% vs. 33.7% vs. 29.9%, respectively) during the first 6 months overall. Increases in HMWA were associated with reductions in glycemic failure in the three racial/ethnic groups combined (hazard ratio 0.61, P < 0.0001) and in each race/ethnicity separately. Over time, HMWA was significantly lower in those who failed versus did not fail treatment, irrespective of race/ethnicity. There were no differences in treatment-associated temporal changes in insulin sensitivity, C-peptide index, and oDI among the three racial/ethnic groups. CONCLUSIONS: HMWA is a reliable biomarker of treatment response in youth with type 2 diabetes. The diminutive treatment-associated increase in HMWA in NHB (∼50% lower) compared with NHW and H may explain the observed racial/ethnic disparity with higher therapeutic failure rates in NHB in TODAY.
OBJECTIVE: The Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) study demonstrated that glycemic failure rates in the three treatments combined-metformin plus rosiglitazone, metformin alone, and metformin plus lifestyle-were higher in non-Hispanic blacks (NHB; 52.8%) versus non-Hispanic whites (NHW; 36.6%) and Hispanics (H; 45.0%). Moreover, metformin alone was less effective in NHB versus NHW versus H youth. This study describes treatment-associated changes in adiponectin, insulin sensitivity, and β-cell function over time among the three racial/ethnic groups to understand potential mechanism(s) responsible for this racial/ethnic disparity. RESEARCH DESIGN AND METHODS: TODAY participants underwent periodic oral glucose tolerance tests to determine insulin sensitivity, C-peptide index, and oral disposition index (oDI), with measurements of total and high-molecular-weight adiponectin (HMWA). RESULTS: At baseline NHB had significantly lower HMWA than NHW and H and exhibited a significantly smaller increase (17.3% vs. 33.7% vs. 29.9%, respectively) during the first 6 months overall. Increases in HMWA were associated with reductions in glycemic failure in the three racial/ethnic groups combined (hazard ratio 0.61, P < 0.0001) and in each race/ethnicity separately. Over time, HMWA was significantly lower in those who failed versus did not fail treatment, irrespective of race/ethnicity. There were no differences in treatment-associated temporal changes in insulin sensitivity, C-peptide index, and oDI among the three racial/ethnic groups. CONCLUSIONS: HMWA is a reliable biomarker of treatment response in youth with type 2 diabetes. The diminutive treatment-associated increase in HMWA in NHB (∼50% lower) compared with NHW and H may explain the observed racial/ethnic disparity with higher therapeutic failure rates in NHB in TODAY.
Authors: Kenneth C Copeland; Philip Zeitler; Mitchell Geffner; Cindy Guandalini; Janine Higgins; Kathryn Hirst; Francine R Kaufman; Barbara Linder; Santica Marcovina; Paul McGuigan; Laura Pyle; William Tamborlane; Steven Willi Journal: J Clin Endocrinol Metab Date: 2010-10-20 Impact factor: 5.958
Authors: Bruce B Duncan; Maria Inês Schmidt; James S Pankow; Heejung Bang; David Couper; Christie M Ballantyne; Ron C Hoogeveen; Gerardo Heiss Journal: Diabetes Date: 2004-09 Impact factor: 9.461
Authors: Tania S Burgert; Elvira J Duran; Rachel Goldberg-Gell; James Dziura; Catherine W Yeckel; Stuart Katz; William V Tamborlane; Sonia Caprio Journal: Pediatr Diabetes Date: 2008-08-27 Impact factor: 4.866
Authors: Hannah Gardener; Milita Crisby; Charlotte Sjoberg; Barry Hudson; Ronald Goldberg; Armando J Mendez; Clinton B Wright; Tatjana Rundek; Mitchell S V Elkind; Ralph L Sacco Journal: Metab Syndr Relat Disord Date: 2012-11-05 Impact factor: 1.894
Authors: Ruban Dhaliwal; John A Shepherd; Laure El Ghormli; Kenneth C Copeland; Mitchell E Geffner; Janine Higgins; Lynne L Levitsky; Kristen J Nadeau; Ruth S Weinstock; Neil H White Journal: Diabetes Care Date: 2019-06-05 Impact factor: 19.112
Authors: Fida Bacha; Laure El Ghormli; Silva Arslanian; Philip Zeitler; Lori M Laffel; Lorraine E Levitt Katz; Rachelle Gandica; Nancy T Chang; Jennifer E Sprague; Sarah A Macleish Journal: Pediatr Diabetes Date: 2019-08-27 Impact factor: 4.866
Authors: Silva Arslanian; Laure El Ghormli; Morey H Haymond; Christine L Chan; Steven D Chernausek; Rachelle G Gandica; Rose Gubitosi-Klug; Lynne L Levitsky; Maggie Siska; Steven M Willi Journal: Pediatr Diabetes Date: 2020-03-03 Impact factor: 4.866
Authors: Silva Arslanian; Laure El Ghormli; Joon Young Kim; Fida Bacha; Christine Chan; Heba M Ismail; Lorraine E Levitt Katz; Lynne Levitsky; Jeanie B Tryggestad; Neil H White Journal: Diabetes Care Date: 2018-11-19 Impact factor: 19.112
Authors: Maria J Redondo; Megan V Warnock; Ingrid M Libman; Laura E Bocchino; David Cuthbertson; Susan Geyer; Alberto Pugliese; Andrea K Steck; Carmella Evans-Molina; Dorothy Becker; Jay M Sosenko; Fida Bacha Journal: Diabetes Care Date: 2021-07-29 Impact factor: 17.152